Glutamatergic Modulation in Alzheimer’s Disease Pathophysiology

Alzheimer’s disease (AD) is characterised by progressive cognitive decline underpinned by amyloid-β deposition, tau pathology and synaptic failure. Central to synaptic dysfunction is dysregulation of the glutamatergic system, in which the excitatory neurotransmitter glutamate accumulates in the extracellular space and overactivates postsynaptic receptors. Failure of astrocytic and neuronal glutamate transporters permits spill-over at the synaptic cleft, driving excitotoxic cascades, calcium overload and eventual neuronal loss. Modulation of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors offers symptomatic relief, yet does not arrest underlying pathology. Emerging strategies focus on restoring glutamate clearance, bolstering astrocyte function and ameliorating presynaptic vulnerabilities. Together, these approaches seek to rebalance excitatory–inhibitory tone and protect neuronal networks at early stages of disease.

Research from Nature Portfolio

In vivo imaging studies employing genetically encoded glutamate sensors have mapped regions surrounding amyloid-β plaques, revealing chronic elevations of extracellular glutamate and slowed clearance kinetics. Reduced expression of the dominant astrocytic transporter leads to heightened excitotoxic risk, while pharmacological upregulation of transporter activity by β-lactam antibiotics partially normalises glutamate transients and restores synaptic responsiveness. Complementary post-mortem analyses of human cortex distinguish individuals with preserved cognition despite AD pathology. In these cases, astrocytes display a hypertrophic morphology and enhanced transporter expression, suggesting that an activated glial phenotype confers resilience by maintaining extracellular glutamate homeostasis even in the presence of plaques and tangles.

Glutamatergic Modulation in Alzheimer’s Disease Pathophysiology publication trend

The graph below shows the total number of articles in glutamatergic modulation in alzheimer’s disease pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Glutamate transporter-1 (GLT-1): Astrocytic membrane protein responsible for high-affinity uptake of extracellular glutamate.

Excitotoxicity: Neuronal damage caused by sustained activation of glutamate receptors leading to calcium overload.

Astrocyte: Star-shaped glial cell that supports neurotransmitter clearance, ion balance and metabolic coupling.

Synaptic cleft: Narrow extracellular space between pre- and postsynaptic membranes where neurotransmitters are released.

iGluSnFR: Genetically encoded fluorescent sensor used to visualise real-time glutamate dynamics in living tissue.

References

1. Alzheimer’s disease: targeting the glutamatergic system. Biogerontology (2020).
2. Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Aβ plaques by iGluSnFR two-photon imaging. Nature Communications (2016).
3. Sulbactam protects neurons against double neurotoxicity of amyloid beta and glutamate load by upregulating glial glutamate transporter 1. Cell Death Discovery (2024).
4. Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain. Scientific Reports (2018).
5. Astrocytic proteins involved in regulation of the extracellular environment are increased in the Alzheimer's disease middle temporal gyrus. Neurobiology of Disease (2024).
6. Asymmetric dysregulation of glutamate dynamics across the synaptic cleft in a mouse model of Alzheimer’s disease. Acta Neuropathologica Communications (2023).